An Open Label, Dose-Escalation Safety and Pharmacokinetic Study of AVE9633 Administered as a Single Agent by Intravenous Infusion on Day 1, Day 4 and Day 7 of a 4-Week Cycle in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia (AML).
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2014
At a glance
- Drugs AVE 9633 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Sanofi
- 15 May 2009 Actual end date (Aug 2008) added as reported by ClinicalTrials.gov record.
- 15 May 2009 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 16 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.